Intervention
Upadacitinib
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 19 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
19 shownImmunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyNCT07138898 · 2025-12-12
RECRUITINGApplication of the Personalized N-of-1 Trial Design in Patients With Rheumatoid ArthritisNCT06016517 · 2026-09-01
NOT_YET_RECRUITINGActive Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib)NCT06498167 · 2024-07-01
UNKNOWNStudy to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid ArthritisNCT05814627 · 2023-06-15
COMPLETEDEarly Changes in Pain, Disease Activity, and Ultrasound Evidence of Inflammatory Synovitis in Patients Receiving JAK-inhibitor vs. TNF-inhibitor Therapy for Active Rheumatoid Arthritis: A Feasibility Study.NCT05153200 · 2022-01-01
UNKNOWNCOVID-19 VaccinE Response in Rheumatology PatientsNCT05080218 · 2021-11-15
COMPLETEDA Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With UpadacitinibNCT03823378 · 2019-05-13
TERMINATEDA Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid ArthritisNCT03682705 · 2018-10-08
COMPLETEDA Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)NCT02955212 · 2018-01-03
COMPLETEDA Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDsNCT03086343 · 2017-05-09
COMPLETEDA Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)NCT02706951 · 2016-03-23
COMPLETEDA Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDsNCT02720523 · 2016-03-22
COMPLETEDA Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDsNCT02706847 · 2016-03-15
COMPLETEDA Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken MethotrexateNCT02706873 · 2016-02-23
COMPLETEDA Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs AloneNCT02675426 · 2015-12-17
COMPLETEDA Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to MethotrexateNCT02629159 · 2015-12-01
ACTIVE_NOT_RECRUITINGA Study Investigating the Efficacy and Safety of Upadacitinib (ABT-494) Given With Methotrexate (MTX) in Adults With Rheumatoid Arthritis Who Have Had an Inadequate Response to MTX AloneNCT02066389 · 2014-03-26
COMPLETEDAn Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Adults With Rheumatoid ArthritisNCT02049138 · 2014-01-24
COMPLETEDExpanded Access to UpadacitinibNCT04159597
AVAILABLECommon conditions
Rheumatoid Arthritis12Rheumatoid Arthritis (RA)4Psoriatic Arthritis2Adverse Drug Event1Adverse Drug Reaction1Alopecia Areata1Arthritis, Rheumatoid1Atopic Dermatitis1Axial Spondyloarthritis1Crohn Disease1Drug Side Effect1Drug Use1Giant Cell Arteritis1Hidradenitis Suppurativa1Idiopathic Arthritis (Including sJIA, pJIA, or JPsA)1Inflammatory Disease1Non Segmental Vitiligo1Non-radiographic Axial1Rheumatic Disease1Safety Issues1Spondylarthritis1Spondyloarthritis1Systemic Lupus Erythematosus1Ulcerative Colitis1
Leading sponsors
Trial status mix
COMPLETED12
UNKNOWN2
ACTIVE_NOT_RECRUITING1
AVAILABLE1
NOT_YET_RECRUITING1
RECRUITING1
TERMINATED1
Phase mix
PHASE39
PHASE26
PHASE42
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.